Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11846MR)

This product GTTS-WQ11846MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11846MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7447MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ9051MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ866MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ11672MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ1446MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ14636MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ547MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ13326MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06741086
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW